PMID- 38293770
OWN - NLM
STAT- MEDLINE
DCOM- 20240325
LR  - 20240325
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 44
IP  - 4
DP  - 2024 Apr
TI  - Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their 
      antidiabetic use.
PG  - 884-893
LID - 10.1111/liv.15851 [doi]
AB  - Type 2 diabetes mellitus (T2DM) and liver cirrhosis are clinical entities that 
      frequently coexist, but glucose-lowering medication options are limited in 
      cirrhotic patients. Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a 
      class of glucose-lowering medication that act independently of insulin, by 
      causing glycosuria in the proximal convoluted tubule. In this review, we aimed to 
      briefly present the main data and to provide insight into the pathophysiology and 
      potential usefulness of SGLT2 inhibitors in cirrhotic patients with or without 
      T2DM. SGLT2 inhibitors have been proven useful as antidiabetic treatment in 
      patients with metabolic liver disease, with most robust data from patients with 
      metabolic dysfunction-associated steatotic liver disease (MASLD), where they also 
      showed improvement in liver function parameters. Moreover, it has been suggested 
      that SGLT2 inhibitors may have effects beyond their antidiabetic action. 
      Accordingly, they have exhibited cardioprotective effects, expanding their 
      indication in patients with heart failure without T2DM. Since decompensated liver 
      cirrhosis and congestive heart failure share common pathophysiological features, 
      namely renin-angiotensin-aldosterone axis and sympathetic nervous system 
      activation as well as vasopressin secretion, SGLT2 inhibitors could also be 
      beneficial in patients with decompensated cirrhosis, even in the absence of T2DM.
CI  - (c) 2024 The Authors. Liver International published by John Wiley & Sons Ltd.
FAU - Siafarikas, Christos
AU  - Siafarikas C
AD  - 1st Propaedeutic Department of Internal Medicine, Medical School of National and 
      Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, 
      Greece.
FAU - Kapelios, Chris J
AU  - Kapelios CJ
AD  - Heart Failure and Heart Transplantation Unit, Onassis Cardiac Surgery Center, 
      Athens, Greece.
FAU - Papatheodoridi, Margarita
AU  - Papatheodoridi M
AUID- ORCID: 0000-0001-8581-6591
AD  - Department of Gastroenterology, Medical School of National and Kapodistrian 
      University of Athens, General Hospital of Athens "Laiko", Athens, Greece.
FAU - Vlachogiannakos, John
AU  - Vlachogiannakos J
AUID- ORCID: 0000-0003-3680-8194
AD  - Department of Gastroenterology, Medical School of National and Kapodistrian 
      University of Athens, General Hospital of Athens "Laiko", Athens, Greece.
FAU - Tentolouris, Nikolaos
AU  - Tentolouris N
AD  - 1st Propaedeutic Department of Internal Medicine, Medical School of National and 
      Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, 
      Greece.
FAU - Papatheodoridis, George
AU  - Papatheodoridis G
AUID- ORCID: 0000-0002-3518-4060
AD  - Department of Gastroenterology, Medical School of National and Kapodistrian 
      University of Athens, General Hospital of Athens "Laiko", Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240131
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 0 (Glucosides)
RN  - IY9XDZ35W2 (Glucose)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Humans
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use/pharmacology
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Canagliflozin/therapeutic use
MH  - Glucosides/pharmacology/therapeutic use
MH  - Glucose/metabolism
MH  - *Heart Failure
MH  - Liver Cirrhosis/complications/drug therapy
MH  - Sodium
OTO - NOTNLM
OT  - SGLT2 inhibitor
OT  - cirrhosis
OT  - diabetes
OT  - heart failure
OT  - natriuresis
EDAT- 2024/01/31 06:43
MHDA- 2024/03/25 06:42
CRDT- 2024/01/31 04:38
PHST- 2024/01/02 00:00 [revised]
PHST- 2023/06/16 00:00 [received]
PHST- 2024/01/15 00:00 [accepted]
PHST- 2024/03/25 06:42 [medline]
PHST- 2024/01/31 06:43 [pubmed]
PHST- 2024/01/31 04:38 [entrez]
AID - 10.1111/liv.15851 [doi]
PST - ppublish
SO  - Liver Int. 2024 Apr;44(4):884-893. doi: 10.1111/liv.15851. Epub 2024 Jan 31.